Health Condition 1: E785- Hyperlipidemia, unspecified
Conditions
Interventions
Intervention1: Rosuvastatin: alternate day administration of 10 mg orally once at night to adult patients with dyslipidemia for 6 weeks
Control Intervention1: Rosuvastatin: daily administration of 10
Sponsors
George T Varghese
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients willing to give written informed consent. 2. Patients aged more than 18 and less than or equal to 65 years. 3. Treatment naive patients of dyslipidemia in low to moderate risk group as diagnosed by NCEP ATP III guidelines
Exclusion criteria
Exclusion criteria: 1. Patients unwilling to give written informed consent. 2. Patients with a documented history of acute coronary syndrome, cerebrovascular accident, on-going angina. 3. Pregnant and lactating mothers. 4. Patients on co-existing medication which aggravate statin myopathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage reduction in LDL-C 2. Changes in other lipid markers like total cholesterol, triglycerides, HDL-C Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Number and severity of adverse events reported by the patient at any time during the study.Timepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr George T Varghese
Bangalore Medical College and Research Institute
Outcome results
None listed